Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

TypePublic
HQFoster City, US
Founded1987
Size (employees)9,000 (est)
Websitegilead.com
Gilead Sciences was founded in 1987 and is headquartered in Foster City, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Gilead Sciences

John F. Milligan

John F. Milligan

President and Chief Executive Officer
Gregg H. Alton

Gregg H. Alton

Chief Patient Officer
Andrew Dickinson

Andrew Dickinson

Executive Vice President, Corporate Development and Strategy
Laura Hamill

Laura Hamill

Executive Vice President, Worldwide Commercial Operations
William A. Lee

William A. Lee

Executive Vice President, Research
AO John McHutchison

AO John McHutchison

Chief Scientific Officer, Head of Research and Development
Show more

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations
Foster City, US (HQ)
333 Lakeside Dr
Branford, US
36 E Industrial Rd
Fremont, US
7601 Dumbarton Cir
Oceanside, US
4049 Avenida De La Plata
San Dimas, US
650 Cliffside Dr
Seattle, US
199 E Blaine St
Show all (6)
Report incorrect company information

Gilead Sciences Financials and Metrics

Gilead Sciences Revenue

Embed Graph
Gilead Sciences's revenue was reported to be $26.11 b in FY, 2017
USD

Revenue (Q1, 2018)

5.1 b

Gross profit (Q1, 2018)

4.1 b

Gross profit margin (Q1, 2018), %

80.3%

Net income (Q1, 2018)

1.5 b

EBIT (Q1, 2018)

2.2 b

Market capitalization (21-Sep-2018)

97.9 b

Closing stock price (21-Sep-2018)

75.5

Cash (31-Mar-2018)

7.6 b

EV

116.8 b
Gilead Sciences's current market capitalization is $97.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.2 b24.9 b32.6 b30.4 b26.1 b

Revenue growth, %

122%31%(7%)

Cost of goods sold

2.9 b3.8 b4 b4.3 b4.4 b

Gross profit

8.3 b21.1 b28.6 b26.1 b21.7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

2.8 b5 b6.5 b6 b7.6 b8.2 b8.3 b7.8 b7.8 b7.5 b6.5 b7.1 b5.1 b

Cost of goods sold

681.9 m813.2 m924.7 m987.3 m882 m998 m1.1 b1.2 b864 m1.1 b957 m1.1 b1 b

Gross profit

2.1 b4.2 b5.6 b5.1 b6.7 b7.2 b7.2 b6.6 b6.9 b6.4 b5.5 b6 b4.1 b

Gross profit Margin, %

75%84%86%84%88%88%87%85%89%85%85%84%80%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.1 b10 b12.9 b8.2 b7.6 b

Inventories

2.1 b1.4 b2 b1.6 b801 m

Current Assets

7.3 b17.7 b24.8 b20.4 b31.8 b

PP&E

1.2 b1.7 b2.3 b2.9 b3.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

2 b6.4 b8.7 b6.2 b10.6 b7.4 b14 b6.3 b6.5 b9.8 b10.3 b8.7 b7.6 b

Accounts Receivable

2 b3.2 b3.4 b2.9 b4.8 b5.3 b6.1 b

Inventories

1.9 b2.1 b2.1 b1.9 b1.9 b2 b2 b1.9 b1.9 b1.9 b1.5 b1.4 b885 m

Current Assets

7 b13 b15.5 b12.6 b20.1 b18.1 b25.9 b19.3 b18.4 b21.4 b21.4 b28.6 b30.3 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.1 b12.1 b18.1 b13.5 b4.6 b

Depreciation and Amortization

233 m

Inventories

(343.1 m)143 m(855 m)(488 m)(253 m)

Accounts Payable

(97.7 m)(289 m)226 m47 m(430 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

785.2 m2.2 b3.7 b2.7 b4.3 b8.8 b13.4 b3.6 b7.1 b10.4 b2.7 b5.8 b1.5 b

Depreciation and Amortization

75 m116 m42 m85 m129 m49 m103 m56 m

Inventories

(634 m)(659 m)(14 m)(97 m)(274 m)(5 m)(14 m)(14 m)

Accounts Payable

620 m288 m(239 m)(67 m)(115 m)(262 m)(399 m)(92 m)
USDY, 2018

EV/EBIT

54.3 x

EV/CFO

51.5 x

EV/FCF

56.8 x

Financial Leverage

3.2 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016

Countries

30

Phase I Trials Products

3

Phase II Trials Products

12

Phase III Trials Products

6
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Kite PharmaAugust 28, 2017$11.90 b

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by geographic segment: 20.9% from Europe, 63.7% from United States, 8.3% from Japan and 7.1% from Other

Report incorrect company information

Gilead Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Gilead Sciences News and Updates

Nota de esclarecimento da Gilead Sciences sobre o tratamento da Hepatite C no Brasil

SÃO PAULO, 24 de setembro de 2018 /PRNewswire/ -- A Gilead refuta as acusações de prática abusiva de preços e exploração indevida da patente para medicamento de tratamento da Hepatite C, conforme veiculado na imprensa. Acreditamos no caráter inovador dos nossos fármacos e confiamos que os ...

Alcoholic Hepatitis Pipeline Review| Companies Involved in Therapeutics Development: DURECT Corp, Generon Corp Ltd, Gilead Sciences

Alcoholic Hepatitis Pipeline Review Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday

Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related benefits - - Substantive spleen and symptom control in JAK inhibitor naïve myelofibrosis...
Show more
Report incorrect company information

Gilead Sciences Company Life and Culture

Report incorrect company information